GlassScriptPhysician profile
Daniel A Hirselj
NPI 1962603175
$1,368.53
in general payments reported to CMS, 2019-2025
28 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Pediatric Urology provider received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $94.04 · 2021: $236 · 2022: $131 · 2023: $120 · 2024: $300 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $527.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $153.02 | 2019-2024 | Rezum Generator, Greenlight Xps |
| Dendreon Pharmaceuticals LLC | $135.09 | 2021-2025 | Provenge |
| Abbvie INC. | $95.99 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $84.89 | 2019-2022 | |
| Accord Healthcare, INC. | $81.30 | 2024 | |
| Janssen Scientific Affairs, LLC | $68.30 | 2019-2020 | |
| Convatec INC. | $62.64 | 2021-2025 | |
| Tolmar, INC. | $57.70 | 2024-2025 | Jatenzo, Eligard |
| Karl Storz Endoscopy-America | $57.55 | 2019-2020 | |
| Palette Life Sciences, INC. | $56.90 | 2019-2022 | |
| Coloplast Corp | $54.00 | 2019-2023 | Self-Cath |
| Merck Sharp & Dohme LLC | $49.93 | 2024 | Lynparza, Keytruda |
| Myriad Genetic Laboratories, INC. | $46.92 | 2021-2023 | Prolaris |
| Bayer Healthcare Pharmaceuticals INC. | $45.60 | 2019 | |
| Janssen Biotech, INC. | $36.33 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $34.68 | 2024 | |
| Teleflex LLC | $34.67 | 2021 | |
| Smith+Nephew, INC. | $31.89 | 2021-2022 | |
| Amgen INC. | $30.66 | 2020 | |
| Blue Earth Diagnostics | $22.61 | 2021 | |
| Alnylam Pharmaceuticals INC. | $21.33 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $19.67 | 2021 | |
| Endo Pharmaceuticals INC. | $19.09 | 2019 | |
| Ferring Pharmaceuticals INC. | $15.90 | 2019 | |
| Angiodynamics, INC. | $15.60 | 2021 | |
| Antares Pharma, INC. | $14.78 | 2019 | |
| Ambu INC. | $13.49 | 2022 | |
| Travere Therapeutics, INC. | $8.00 | 2019-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hirselj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.